Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 6/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27231638 | 1.00 | BCL6 (0.45) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL30894236 | 1.00 | BCL6 (0.45) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL31595540 | 0.94 | BCL6 (0.48) | BCL6NCOR2MELKCRBNCDK12 | |
| SCHEMBL23267390 | 0.94 | BCL6 (0.48) | BCL6NCOR2MELKCRBNCDK12 | |
| SCHEMBL31595513 | 0.92 | BCL6 (0.45) | BCL6NCOR2MELKCRBNCDK12 | |
| SCHEMBL23267432 | 0.92 | BCL6 (0.45) | BCL6NCOR2MELKCRBNCDK12 | |
| SCHEMBL31595229 | 0.92 | BCL6 (0.45) | BCL6NCOR2MELKCRBNCDK12 | |
| SCHEMBL24717888 | 0.92 | BCL6 (0.48) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL30894313 | 0.92 | BCL6 (0.48) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL27231483 | 0.92 | BCL6 (0.48) | BCL6NCOR2MELKCHRM4BCL6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | BCL6 1/4885NCOR2 620/4885MELK 619/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | BCL6 1/4885NCOR2 620/4885MELK 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.